Introduction: An association between type 2 diabetes and osteoarthritis has been postulated. The present umbrella review of systematic reviews and meta-analyses investigated possible bidirectional relationships between type 2 diabetes and osteoarthritis.
Methods: PubMed, Scopus, Web of Science, and Cochrane Library databases were accessed. All the available systematic reviews and meta-analyses on the relationship between type 2 diabetes and osteoarthritis were accessed. The odds ratio (OR) effect measure and 95% confidence interval (CI) were used for the statistical analyses.
Results: Four systematic reviews, of whom three meta-analyses, were considered. Data from 26209 patients with osteoarthritis were considered: 3530 with type 2 diabetes and 22679 without type 2 diabetes. A significantly increased rate of osteoarthritis was evidenced in patients with type 2 diabetes than in patients without it (OR = 1.43; 95% CI 1.01 to 2.02). The effect persisted after in the subgroups age, sex, and obesity (pooled adjusted OR = 1.22; 95% CI 1.05 to 1.42).
Conclusion: Patients with type 2 diabetes might present an increased risk of developing osteoarthritis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00590-025-04231-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Benefits and Accuracy of Real-Time CGM in Children and Adolescents with Type 1 Diabetes Attending Summer Camp: 2nd year.
J Clin Endocrinol Metab
March 2025
Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University. 1-1-1 Honjo, Chuo-ku, Kumamoto 860-8556, Japan.
Context: In 2023, we employed Dexcom G6 for real-time continuous glucose monitoring (rt-CGM); it showed high usefulness but unsatisfactory accuracy in type 1 diabetes summer camp (camp) participants.
Objective: To assess the usefulness, recommendation and accuracy of a new rt-CGM system in camp, 2024.
Methods: Sensor glucose (SG) concentrations were measured by Dexcom G7 (G7) from 6 days prior to camp.
Association of family history of cardiovascular disease with the prevalence of cardiometabolic risk factors in young adults in the United Arab Emirates: The UAE healthy future study.
PLoS One
March 2025
Public Health Research Center, New York University Abu Dhabi, Abu Dhabi, United Arab Emirates.
Introduction: Family history of cardiovascular disease (CVD) is an independent risk factor for coronary heart disease, and the risk increases with number of family members affected. It offers insights into shared genetic, environmental and lifestyle factors that influence heart disease risk. In this study, we aimed to estimate the association of family history of CVD and its risk factors, as well as the number of affected parents or siblings, with the prevalence of major cardiometabolic risk factors (CRFs) such as hypertension, dysglycemia, dyslipidemia and obesity in a sample of young adults.
View Article and Find Full Text PDFEarly expansion of TIGIT+PD1+ effector memory CD4 T cells via agonistic effect of alefacept in new-onset type 1 diabetes.
J Immunol
January 2025
Center for Translational Immunology, Benaroya Research Institute, Seattle, WA, United States.
The CD2-depleting drug alefacept (LFA3-Ig) preserved beta cell function in new-onset type 1 diabetes (T1D) patients. The most promising biomarkers of response were late expansion of exhausted CD8 T cells and rare baseline inflammatory islet-reactive CD4 T cells, neither of which can be used to measure responses to drug in the weeks after treatment. Thus, we investigated whether early changes in T cell immunophenotypes could serve as biomarkers of drug activity.
View Article and Find Full Text PDFImpact of obesity on the CCR6-CCL20 axis in epidermal γδ T cells and IL-17A production in murine wound healing and psoriasis.
J Immunol
January 2025
Department of Biological Sciences, California State University San Marcos, San Marcos, CA, United States.
Obesity is associated with comorbidities including type 2 diabetes, chronic nonhealing wounds, and psoriasis. Normally, skin homeostasis and repair is regulated through the production of cytokines and growth factors derived from skin-resident cells including epidermal γδ T cells. However, epidermal γδ T cells exhibit reduced proliferation and defective growth factor and cytokine production during obesity and type 2 diabetes.
View Article and Find Full Text PDFEffects of PARP1 inhibitor PJ-34 on TGFα, IL-6, and IL-1β levels in diabetic nephropathy.
J Immunol
February 2025
Orthopedics Department, Central Hospital of Ezhou, Ezhou, China.
Diabetic nephropathy is a severe chronic complication characterized by cytotoxicity, inflammation, and fibrosis, ultimately leading to renal failure. This study systematically investigated the effects of the PARP1 inhibitor PJ-34 on high glucose-induced cytotoxicity, inflammation, and fibrosis in HK-2 cells, as well as its improvement on neuropathic pain response and transforming growth factor β (TGFβ) expression in a type 1 diabetes mellitus diabetic nephropathy mouse model. Through cellular and animal experiments, we observed that PJ-34 significantly enhanced the proliferative capacity of cells damaged by high glucose, reduced apoptosis, and decreased the release of proinflammatory factors TGFα, interleukin-6, and interleukin-1β.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!